Use of Bevacizumab (Avastin) in the Treatment of Metastatic Breast Cancer

Please note: All assessments are current as of the review date; however, new evidence that may have been published subsequently is not considered.
Review Date:	June 18, 2008
Recommendation:	This topic was reviewed by the California Technology Assessment Forum on June 18, 2008. It is recommended that the use of bevacizumab as initial or second-line treatment for metastatic breast cancer does not meet CTAF Technology Assessment Criteria 3 through 5 for safety, effectiveness and improvement in health outcomes.
Decision:	Does Not Meet CTAF Criteria
Full Assessment:	Download (PDF)

Search Assessments